Daniel Vaena is an Oncology physician affiliated with West Cancer Center. OpenAlex indexes 113 publications with 5,153 citations (h-index 19); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7945 Wolf River Blvd
Germantown, TN 381381733
Telephone
901-683-0055Registry record last updated 14 Oct 2016.
Clinical trials
- PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy
Sponsor: Daniel Vaena
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
27 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202511 payments
- AVYXA PHARMA, LLCProgram year20257 payments
- Janssen Biotech, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
64%PD-1 inhibitor33.9%Pembrolizumab60%Nivolumab40%Part B, office-administered≥50 patientsMicrotubule Inhibitor10.8%Paclitaxel76%Docetaxel24%Part B, office-administered≥29 patients+ 13 more classes in this area
Blood & clotting
17.1%Erythropoiesis-stimulating Agent15.8%Darbepoetin alfa100%Part B, office-administered≥51 patientsIron, parenteral preparations1.3%Ferric derisomaltose100%Part B, office-administered≥12 patients+ 1 more class in this area
Musculoskeletal
7%RANK Ligand Inhibitor6.9%Denosumab100%Part B, office-administered≥66 patientsBisphosphonate0.1%Zoledronic acid100%Part B, office-administered≥16 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Ari Vanderwalde, MD
West Cancer Center
Gregory Vidal, MD
West Cancer Center
David Portnoy, MD
West Cancer Center
Noam Vanderwalde, MD
West Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”